Oct 19, 2026 07:00AM
Oct 19, 2026 07:00AM
Sep 22, 2026 08:03AM
Sep 22, 2026 08:00AM
Aug 21, 2026 07:04AM
May 20, 2026 06:49AM
Mar 23, 2026 06:48AM H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)
Mar 18, 2026 05:31PM
Nov 14, 2025 07:00AM
Oct 6, 2025 07:45AM
Oct 6, 2025 07:30AM
May 19, 2025 08:00AM
Dec 17, 2024 07:01AM
Dec 17, 2024 07:00AM Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Dec 17, 2024 07:00AM
Aug 14, 2024 04:30PM
May 15, 2024 04:15PM
Apr 30, 2024 06:46AM
Mar 25, 2024 05:45PM
Jan 8, 2024 08:25AM
Jan 8, 2024 08:24AM Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Dec 21, 2023 11:00AM
Dec 11, 2023 07:05AM
Dec 11, 2023 07:00AM
Nov 9, 2023 05:00PM
Aug 14, 2023 04:30PM
Aug 7, 2023 07:13AM
Aug 7, 2023 07:00AM Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
Jul 10, 2023 07:02AM
Jul 10, 2023 07:00AM
Jun 26, 2023 07:10AM
Jun 26, 2023 07:00AM
May 31, 2023 06:34AM
May 31, 2023 06:30AM
May 1, 2023 07:31AM Marker Therapeutics (MRKR) Announces Non-Dilutive Agreement With CellReady
May 1, 2023 07:30AM
Mar 22, 2023 08:10AM
Nov 22, 2022 07:04AM
Nov 22, 2022 07:00AM
Nov 10, 2022 04:05PM
Sep 13, 2022 07:02AM
Sep 13, 2022 07:00AM Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
Aug 11, 2022 04:22PM
Aug 4, 2022 04:39PM
Aug 4, 2022 04:37PM
Jun 23, 2022 09:00AM
Apr 26, 2022 07:00AM
Mar 18, 2022 05:57AM
Mar 17, 2022 05:45PM Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
Feb 16, 2022 04:31PM

335,242 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All